Skip to content

GDF-15 levels as prognostic marker in patients with Atrial Fibrillation

Growth differentiation factor-15 in Assessment of Prognosis of patients with Atrial Fibrillation (GAP-AF Study)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-106xbn9s
Enrollment
Unknown
Registered
2023-02-01
Start date
2021-04-10
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth and differentiation Factor-15

Interventions

We measured GDF-15 at hospital admission in 50 patients hospitalized for atrial fibrillation in 2 private hospitals at the city of Niterói, and we observed the occurrence of mortality, thrombosis and
V03.175.500

Sponsors

Universidade Federal Fluminense
Lead Sponsor
Universidade Federal Fluminense
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Hospitalized patients with a primary or secondary or secondary diagnosis of acute, paroxysmal or permanent Atrial Fibrillation; aged 18 years or older.

Exclusion criteria

Exclusion criteria: Presence of associated terminal disease (malignant neoplasms or others); pregnancy.

Design outcomes

Primary

MeasureTime frame
Expected outcome 1: It is expected to find an increase in the number of all-cause mortality events within a year, using the Kaplan-Meyer survival analysis method, especially in patients with biomarker values ??above the median found in the study.; Primary Outcome found: We found 7 deaths during the follow-up. These results will still be submitted to statistical analysis.

Secondary

MeasureTime frame
Secondary Outcome found 3: We FOUND 6 hospital readmissions due to atrial fibrillation or heart failure during the follow-up period. These results will still be submitted to statistical analysis.;Expected secondary outcome 1: It is expected to find an increase in the number of stroke or systemic embolism events, assessed by clinical diagnosis and complementary imaging exams, in the period of one year, using the Kaplan-Meyer analysis method, especially in patients with biomarker values ??above the median. ;Expected secondary outcome 2: It is expected to find an increase in the number of major bleeding events, according to ISTH criteria, in a one-year period, using the Kaplan-Meyer analysis method, especially in patients with biomarker values above the study median. ;Expected secondary outcome 3: It is expected to find an increase in the number of events of new hospitalization due to atrial fibrillation or heart failure, in the period of one year, verified using the Kaplan-Meyer analysis method, especially in patients with biomarker values ??above the study median. ;Expected secondary outcome 4: It is expected to find an increase in the number of death events due to cardiovascular causes, in the period of one year, using the Kaplan-Meyer analysis method, especially in patients with biomarker values ??above the study median. ;Secondary Outcome found 1: We found no embolic new events after the 1-year follow-up period These results will still be submitted to statistical analysis.;Secondary Outcome found 2: There was 1 major bleeding event after the 1-year follow-up period; These results will still be submitted to statistical analysis.;Secondary Outcome found 4: We FOUND 4 deaths due to cardiovascular causes during the follow-up. These results will still be submitted to statistical analysis.

Countries

Brazil

Contacts

Public ContactAngelo di Candia

Universidade Federal Fluminense

angelodicandia@gmail.com55(21)996475853

Outcome results

None listed

Source: REBEC (via WHO ICTRP)